First‐in‐man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M 1 ‐receptor partial agonist for the treatment of dementias-Reference-Cited by-同舟云学术

First‐in‐man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M 1 ‐receptor partial agonist for the treatment of dementias

Published:2021-02-05 Issue:7 Volume:87 Page:2945-2955
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Bakker Charlotte¹^ORCID,Tasker Tim²,Liptrot Jan²,Hart Ellen P.¹,Klaassen Erica S.¹,Prins Samantha¹,Doef Thalia F.¹,Brown Giles A.³,Brown Alastair²,Congreve Miles²,Weir Malcolm²,Marshall Fiona H.⁴,Cross David M.⁵,Groeneveld Geert Jan¹⁶,Nathan Pradeep J.²⁷⁸

Affiliation:

1. Centre for Human Drug Research (CDHR) Leiden Netherlands

2. Sosei Heptares Cambridge UK

3. OMass Therapeutics Ltd Oxford UK

4. Merck Sharp & Dohme Limited London UK

5. Cross Pharma Consulting Limited Cambridge UK

6. Leiden University Medical Centre Leiden The Netherlands

7. Department of Psychiatry University of Cambridge UK

8. School of Psychological Sciences Monash University Australia

Publisher

Wiley

Subject